Table 2.
Histology, ESR and CRP as predictors of outcome among limited-stage patients: All histology and restricted to nodular sclerosis.
| CR (%) | p Value | 4-yr EFS CR no RT | N | p Value | 4-yr EFS PR w RT | N | p Value | 4-yr EFS | N | p Value | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| All histology | |||||||||||
| Histology | 0.35 | 0.009 | 0.3 | 0.008 | |||||||
|
| |||||||||||
| MC | 29 (69.1%) | 96.6% | 29 | 92.3% | 13 | 95.2% | 42 | ||||
|
| |||||||||||
| NS | 108 (61.4) | 72.6% | 98 | 78.9% | 61 | 75.8% | 179 | ||||
|
| |||||||||||
| ESR | 0.18 | 0.009 | 0.86 | 0.02 | |||||||
|
| |||||||||||
| <=20 | 96 (67.6) | 85.0% | 89 | 82.4% | 39 | 85.1% | 143 | ||||
|
| |||||||||||
| >20 | 79 (59.9) | 68.4% | 73 | 82.9% | 48 | 75.1% | 134 | ||||
|
| |||||||||||
| CRP | 0.015 | 0.01 | 0.44 | 0.02 | |||||||
|
| |||||||||||
| <=2x Uln | 120 (70.2) | 82.8% | 111 | 87.1% | 41 | 84.6% | 173 | ||||
|
| |||||||||||
| >2x Uln | 43 (54.4) | 61.7% | 40 | 79.0% | 34 | 70.6% | 80 | ||||
| Nodular Sclerosis | |||||||||||
|
| |||||||||||
| ESR | 0.96 | 0.007 | 0.92 | 0.01 | |||||||
|
| |||||||||||
| <=20 | 52 (61.9) | 85.9% | 46 | 79.6% | 28 | 84.0% | 85 | ||||
|
| |||||||||||
| >20 | 56 (61.5) | 61.4% | 52 | 80.7% | 32 | 69.4% | 93 | ||||
|
| |||||||||||
| CRP | 0.084 | 0.03 | 0.91 | 0.12 | |||||||
|
| |||||||||||
| <=2x Uln | 69 (67.7) | 80.2% | 62 | 80.9% | 28 | 80.9% | 104 | ||||
|
| |||||||||||
| >2x Uln | 33 (54.1) | 56.8% | 31 | 80.0% | 26 | 68.3% | 62 | ||||
Columns correspond to the rate for CR, EFS among subjects that achieved a CR and received no IFRT, EFS among subjects that achieved PR and received protocol IFRT and overall EFS.
Abbreviations: CR, Complete Remission; EFS, Event Free Survival; RT, Radiation Therapy; PR, Partial Remission; ESR, Erythrocyte Sedimentation Rate; CRP, C-Reactive Protein; Uln, Upper Limit of Institutional Normal Range.